| Breakdown Costs |
Lorlatinib |
P-ChT |
Incremental |
| Drug costs |
€72 157 |
€3118 |
€69 039 |
| Administration costs |
€0 |
€390 |
-€390 |
| Monitoring costs |
€1803 |
€294 |
€1509 |
| Adverse event costs |
€24 |
€91 |
-€67 |
| Subsequent therapy costs |
€602 |
€629 |
-€27 |
| Terminal care costs |
€7168 |
€7821 |
-€653 |
| Total costs |
€81 754 |
€12 343 |
€69 411 |
| QALYs |
1.79 |
0.28 |
1.50 |
| LYs |
2.85 |
0.42 |
2.42 |
| ICER per QALY gained |
|
|
€46 102 |
| ICER per LY gained |
|
|
€28 613 |